Transcranial direct current stimulation enhances theory of mind in Parkinson's disease patients with mild cognitive impairment: A randomized, double-blind, sham-controlled study by Adenzato, M. et al.
RESEARCH Open Access
Transcranial direct current stimulation
enhances theory of mind in Parkinson’s
disease patients with mild cognitive
impairment: a randomized, double-blind,
sham-controlled study
Mauro Adenzato1,2†, Rosa Manenti3†, Ivan Enrici4* , Elena Gobbi3, Michela Brambilla3, Antonella Alberici5,
Maria Sofia Cotelli5, Alessandro Padovani5, Barbara Borroni5 and Maria Cotelli3
Abstract
Background: Parkinson’s Disease (PD) with mild cognitive impairment (MCI) (PD-MCI) represents one of the most
dreaded complications for patients with PD and is associated with a higher risk of developing dementia. Although
transcranial direct current stimulation (tDCS) has been demonstrated to improve motor and non-motor symptoms
in PD, to date, no study has investigated the effects of tDCS on Theory of Mind (ToM), i.e., the ability to understand
and predict other people’s behaviours, in PD-MCI.
Methods: In this randomized, double-blind, sham-controlled study, we applied active tDCS over the medial frontal
cortex (MFC) to modulate ToM performance in twenty patients with PD-MCI. Twenty matched healthy controls (HC)
were also enrolled and were asked to perform the ToM task without receiving tDCS.
Results: In the patients with PD-MCI, i) ToM performance was worse than that in the HC, ii) ToM abilities were
poorer in those with fronto-executive difficulties, and iii) tDCS over the MFC led to significant shortening of latency
for ToM tasks.
Conclusions: We show for the first time that active tDCS over the MFC enhances ToM in patients with PD-MCI, and
suggest that non-invasive brain stimulation could be used to ameliorate ToM deficits observed in these patients.
Keywords: Medial frontal cortex (MFC), Mild cognitive impairment (MCI), Parkinson’s disease (PD), Theory of mind
(ToM), Transcranial direct current stimulation (tDCS)
Background
Parkinson’s Disease (PD) is the second most common
neurodegenerative disease [1]. Its cardinal clinical mani-
festations are motors dysfunctions, including resting
tremor, muscle rigidity, akinesia, and postural instability
[2–6]. However, PD is also associated with non-motor def-
icits, including cognitive and emotional impairments,
autonomic dysfunction, sleep disorders, neuropsychiatric
disorders, and sensory impairment [3, 4, 7–16]. Recent
studies have suggested that these symptoms are the major
determinants of quality of life in patients with PD [13, 17].
In recent years, there has been great interest in the
early phases of PD. In particular, PD-mild cognitive im-
pairment (PD-MCI) represents a transitional state be-
tween normal aging and dementia in patients with PD.
This condition is associated with a higher risk of devel-
oping PD with dementia and represents one of the most
dreaded complications of the disease for patients and
caregivers [18]. Interestingly, PD-MCI prevalence seems
to range from 25 to 30% among non-demented patients
with PD [19]. PD-MCI is a heterogeneous clinical
* Correspondence: ivan.enrici@unito.it
†Mauro Adenzato and Rosa Manenti contributed equally to this work.
4Department of Philosophy and Educational Sciences, University of Turin, via
Gaudenzio Ferrari 9, 10124 Turin, Italy
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Adenzato et al. Translational Neurodegeneration             (2019) 8:1 
https://doi.org/10.1186/s40035-018-0141-9
condition and is generally characterized by impairments
in cognitive domains such as memory, visuospatial func-
tion, and frontal/executive functions, with preserved ac-
tivities of daily living [3, 4, 10, 19–23].
Research on the social cognitive profile of PD has re-
vealed disturbances in Theory of Mind (ToM) ability, i.e.,
the ability to attribute mental states to others and to pre-
dict, describe, and explain behaviour on the basis of such
mental states [24–29]. Imaging studies have suggested that
ToM ability relies on a distributed neural network includ-
ing the right and left temporo-parietal junctions, the pre-
cuneus, and the medial frontal cortex (MFC) [30, 31].
Several studies have suggested a pivotal role for the MFC
in ToM (for a review, see [32]).
ToM has attracted considerable interest in neurode-
generative diseases in recent years [33–39]. In particular,
ToM difficulties recorded in patients with PD in the
early stages of the disease principally involve the cogni-
tive component of ToM (i.e., inferences about others’
beliefs and intentions). The spatio-temporal progression
of dopamine depletion in PD supports the hypothesis
that the affective component (i.e., inferences about
others’ emotions and feelings) may only be impaired in
the advanced stages of the disease when depletion of
dopamine in the striatum and the consequent hyposti-
mulation of the MFC also involve more medial portions
of this brain region (the dorsolateral portion of MFC is
affected in early PD stages). Interestingly, it has been
proposed that difficulties in the cognitive component of
ToM, which are detected in ToM tasks in patients with
PD, could be partially explained by the executive func-
tion impairment characterizing the disease [38].
In this study, we applied anodal transcranial direct
current stimulation (tDCS) over the MFC (Fpz site, with
the cathode between Oz and Inion) to modulate ToM
performance in patients with PD-MCI. tDCS is a
non-invasive stimulation technique wherein weak polariz-
ing electrical current externally applied through a pair of
electrodes attached to the head for a few minutes can gen-
erate a change in neuronal excitability and consequently
modulate cognitive task performance. Depending on the
polarity of the current flow, brain excitability can be in-
creased (anode) or decreased (cathode) [40–42].
Several studies have reported short-term modulation of
cognitive performance in typical populations and in pa-
tients using tDCS [43–45]. In addition, a single tDCS ses-
sion has been demonstrated to have an effect on social
cognitive abilities in healthy subjects [46–53]. Although
anodal tDCS has already been demonstrated to improve
motor and non-motor symptoms in PD [54–60], to the
best of our knowledge, no study has yet investigated the
effects of tDCS on ToM abilities in patients with PD-MCI.
To evaluate the impact of active tDCS on ToM
performance in patients with PD-MCI, we used a
video-tape version of a cognitive ToM task to investigate
the ability to represent other individuals’ private and
communicative intentions based on the observation of
daily actions [61–64]. We investigated whether the ap-
plication of active tDCS over the MFC (Fpz site, with
the cathode between Oz and Inion) would facilitate
ToM performance in this study with a double-blind,
sham-controlled experimental design. Based on the PD
cognitive profile described, we hypothesized that, in pa-
tients with PD-MCI, ToM task performance would i) be
worse than it is in healthy controls, ii) correlate with ex-
ecutive functioning, and iii) be enhanced by active tDCS
over the MFC when compared to sham.
Materials and methods
Participants and control group
Twenty patients fulfilling the UK Parkinson’s Disease
Society Brain Bank clinical diagnostic criteria for PD
[65, 66] were consecutively recruited at IRCCS Istituto
Centro San Giovanni di Dio Fatebenefratelli in Brescia,
Italy. Patients with PD-MCI were classified using the
Parkinson’s Disease Cognitive Rating Scale (PD-CRS)
(PD-MCI score range = 65–81 [67]) and using compre-
hensive neuropsychological testing to assess different
cognitive domains (see below) [3].
The exclusion criteria included a) other neurological
and psychiatric disorders; b) history of traumatic brain
injury; c) clinically known hearing or vision impair-
ment or a past history of alcohol abuse; d) diagnosis
of PD-dementia [67] or Mini-Mental Parkinson
(MMP) score < 25 [68, 69]; and e) any contraindication
for tDCS [70]. All patients had been on stable
pharmacological therapy for at least 6 months prior to
entering the study.
Twenty matched healthy controls (HC) were also en-
rolled in the study for behavioural assessment of their
ToM abilities (11 women and 9 men, mean age = 69.4
± 5.8 years, mean education = 11.6 ± 4.4 years). The in-
clusion criteria for the HC were as follows: no history
of mental illness or cognitive decline, no motor or cog-
nitive complaints, normal objective cognitive perform-
ance in all of the administered neuropsychological
tests, normal scores in functional assessment, and ab-
sence of mood and anxiety disorders. The HC were
asked to perform the ToM task without tDCS in order
to allow us to compare ToM abilities in patients with
PD-MCI to those in HC.
All participants were made fully aware of the aims of
the research, and written informed consent was obtained
from all subjects. The study was approved by the local
ethics committee (IRCCS Istituto Centro San Giovanni
di Dio Fatebenefratelli, Brescia, Italy) and was conducted
in accordance with the Declaration of Helsinki.
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Procedure
Clinical and neuropsychological assessment
All patients underwent extensive clinical and neuro-
psychological evaluations carried out over two sessions.
A comprehensive neuropsychological assessment
based on the previously published recommendations is
used [3, 69]. The cognitive tests battery included test for
assessing global cognitive abilities (PD-CRS [71–73])
and tests for memory, language, and attentional and ex-
ecutive functions. We used MMP as a brief screening test
for global cognition [66, 68, 74, 75]. In addition, PD-CRS is
applicable to all stages of PD both for routine clinical prac-
tice and for data collection in clinical trials and it is rated
as “recommended” by the International Parkinson and
Movement Disorder Society [76–78].
The neuropsychological test battery included measures
used to assess verbal fluency (phonemic and semantic),
object and action naming (International Picture Naming
Project, [79]), attention and executive functions (Trail
Making Test, Test of Attentional Performance [TEA]
[80], Stroop Test, Frontal Assessment Battery [FAB]
[81]), and memory (Rey Auditory Verbal Learning Test,
immediate and delayed recall, and Digit Span Forward
and Backward). All of the tests were administered and
scored according to standard procedures [82]. Results of
the neuropsychological assessment of the patients with
PD-MCI are presented in Table 1.
Depressive symptoms were assessed using the Beck
Depression Inventory-II (BDI-II; [83]). Clinical evalu-
ation included the Parkinson’s Disease Quality of Life
Questionnaire-39 [84], the Barratt Impulsivity Scale [85],
the Apathy Evaluation Scale [86], and the Rapid Eye
Movement Sleep Behavior Disorders Screening Ques-
tionnaire (RBDSQ; [83–85, 87]). The Unified Parkinson’s
Disease Rating Scale (UPDRS-III; [88]), the Italian ver-
sion of the 20-Item Toronto Alexithymia Scale (TAS 20;
[89]), the Interpersonal Reactivity Index [90], and the
Hoehn & Yahr Scale [91] were also administered. The
demographic and clinical characteristics of the patients
with PD-MCI are presented in Table 2.
The present work was a randomized, double-blind,
sham-controlled study. Each patient received both ac-
tive and sham tDCS over the MFC (Fpz site, with the
cathode between Oz and Inion) in two different
sessions separated by at least 2 days and in random-
ized order. All patients and the experimenter were
blind to the type of tDCS applied. During each ses-
sion, a video version of a cognitive ToM task was ad-
ministered. According to the literature, tDCS
excitability changes induced by one session of tDCS
applied for a few minutes are expected to last for up
to 1 h [92–94]. Therefore, the performance of the pa-
tients was expected to return to its initial level be-
tween the two sessions of stimulation.
Theory of mind tasks
All of the participants performed two ToM tasks: the
Reading the Mind in the Eyes (RME) task, which was
used to assess individual ToM abilities, and the Attribu-
tion of Intentions (AI) task, which was used to test the
effects of tDCS on cognitive ToM ability.
The RME is an advanced ToM task evaluating the sub-
ject’s ability to represent others’ mental states by observing
only their eyes [95]. The participants were required to
choose which word, among four options, better described
what the character in the photograph was thinking or feel-
ing. The total number of correct choices represented the
RME score. Participants were administered the RME be-
fore the tDCS brain stimulation.
The AI task is a video version of a cognitive ToM task
previously used in young healthy individuals [46]. Partic-
ipants were asked to demonstrate their comprehension
of the displayed stories (short videos lasting 1500 milli-
seconds) by choosing the appropriate story ending (out
of two concluding pictures displayed until the response).
The two possible story endings were shown simultan-
eously until the participant responded by pressing the
corresponding button on the button box as quickly as
possible. The correct picture represented a probable
conclusion, whereas the incorrect picture represented an
improbable ending (see Fig. 1).
The two experimental conditions were a) the Private
Intention condition (PInt), in which participants were
required to recognize another person’s intention while
watching his/her isolated actions, e.g., hanging a picture
on the wall; and b) the Communicative Intention condi-
tion (CInt), in which participants were required to
recognize another person’s communicative intention
during a social interaction, e.g., asking another person to
obtain a glass of water for them.
We displayed 34 video stories for each condition,
for a total of 68 stories using Presentation software
(Version 16.3, www.neurobs.com) running on a per-
sonal computer with a 15-in. screen. Participants were
seated in a quiet room in front of a computer moni-
tor placed 60 cm away from them. The visual location
(right and left side of the screen) of the correct an-
swer was randomized. Accuracy was recorded as the
number of correct trials. The reaction time (RT) for
each correct response was recorded in milliseconds
from the onset of the presentation of the two con-
cluding pictures until detection of the response. The
items were divided into two blocks (17 PInt and 17
CInt stimuli each) corresponding to the two types of
stimulation (active and sham stimulation). Two add-
itional stimuli for each condition were selected for
use in a training session. The stimulation conditions
and the order of the presentation of the two blocks
were randomized across participants. The tests were
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administered on two consecutive days at the same
time of the day to minimize the likelihood of interfer-
ence from confounding factors.
tDCS procedure
Active tDCS was applied using a battery-driven
constant-current stimulator (BrainStim, EMS; Bologna,
Italy) through a pair of saline-soaked sponge electrodes
(7 cm × 5 cm). The target area for tDCS was the MFC
(Montreal National Institute coordinates: 0, 60, 18), as it
has been recognized as a pivotal region in intention pro-
cessing [62–64, 96, 97]. In order to apply tDCS to the
MFC, we placed the anode over Fpz and the cathode
between Inion and Oz (Fig. 1) according to the 10–20
electroencephalography international system [98]. Dur-
ing active tDCS, a constant current of 1.5 mA was ap-
plied for 6 min (with a ramping period of 10 s at the
beginning of the stimulation), starting 2min before the
beginning of the AI task and covering the entire dur-
ation of the task. The current density (0.043 mA/cm2)
was maintained below the safety limits [70]. In the sham
stimulation condition, the tDCS procedure was the
same, but the current was turned off 10 s after the be-
ginning of the stimulation (not including the durations
of the fade-in and fade-out periods = 10 s) and turned on
for the last 10 s of the stimulation period. Therefore, the
Table 1 Neuropsychological assessment of patients with Parkinson’s Disease-mild cognitive impairment (n = 20)
Mean (SD) Cut-off
Screening for dementia
Mini Mental Parkinson 28.0 (2.7) ≥22.85
Global cognitive abilities
Parkinson’s Disease-Cognitive Rating Scale (PD-CRS)
PD-CRS Total Score (max: 134) 78.9 (15.6) ≥82
PD-CRS Cortical Score (max: 30) 26.1 (2.4) –
PD-CRS Frontal Subcortical Score (max: 104) 52.8 (14.0) –
Memory
Rey Auditory Verbal Learning Test, immediate recall 35.8 (11.1) > 28.52
Rey Auditory Verbal Learning Test, delayed recall 7.0 (3.5) > 4.68
Digit Span (Forward) 5.5 (0.9) > 4.25
Digit Span (Backward) 4.1 (0.9) > 2.64
Language
Verbal Fluency, phonemic 30.6 (9.9) > 16
Verbal Fluency, semantic 37.2 (9.0) > 24
Objects Picture Naming task (International Picture Naming Project (IPNP), %) 69.1 (11.9) –
Actions Picture Naming task (IPNP, %) 87.3 (14.2) –
Attentional and Executive Functions
Frontal Assessment Battery 15.3 (2.5) > 13.4
Stroop test (interference effect on time, seconds) 32.4 (14.1) < 36.92
Stroop test (interference effect on error number) 2.4 (3.3) < 4.24
Trail Making Test, part A (seconds) 51.8 (26.5) < 94
Trail Making Test, part B (seconds) 184.7 (125.7) < 283
Test of Attentional Performance
Go/NoGo (time, ms) 528.9 (88.7) –
Go/NoGo (accuracy) 28.2 (2.5) –
Working Memory (time, milliseconds) 803.6 (192.5) –
Working Memory (accuracy) 11.7 (1.1) –
Response Flexibility (time, milliseconds) 1390.4 (512.2) –
Response Flexibility (accuracy) 78.0 (17.8) –
Raw scores are reported. Standard deviation (SD) is presented in parentheses
Cut-off scores according to Italian normative data are reported
Bold data indicate scores below the cut-off value
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participants experienced an itching sensation below the
electrodes at the beginning and end of the stimulation,
making this condition indistinguishable from the experi-
mental stimulation.
The study was a randomized double-blind experiment:
the participants and the experimenter were not aware of
the stimulation that was delivered. The two AI stimuli
sessions corresponded to the two tDCS conditions: ac-
tive and sham tDCS. The stimulation conditions were
randomized across participants and executed on two dif-
ferent days at the same time of day to minimize the like-
lihood of interference from confounding factors. Half of
the male and female participants received active stimula-
tion on day 1 and sham stimulation on day 2, while the
other half of the participants received sham stimulation
on day 1 and active stimulation day 2. Active or sham
tDCS were delivered after a numeric code was input into
the device. This step allowed for blinding of the operator
before and during the tDCS administration.
In order to detect differences in the perception of sen-
sations, to blind the participants to the type of stimula-
tion they were receiving, and to register potential side
effects of tDCS, at the end of the stimulation session we
asked the participants to answer a questionnaire regard-
ing the perceptual sensations they experienced during
the active and sham tDCS experiments.
Statistical analyses
Statistical analyses were performed using Statistica
software (version 10; www.statsoft.com/Products/
STATISTICA-Features). Since the data were normally
distributed (RTs, Kolmogorov-Smirnov Test: d = 0.19, p
= 0.21; and accuracy, Kolmogorov-Smirnov Test: d =
0.16, p > 0.25), AI task performance (accuracy and RT)
was analysed using parametric analyses.
First, AI task performance (accuracy and RT) in the
PD-MCI group under the sham tDCS condition was
compared to that in an age-, sex-, and
education-matched HC group using analysis of variance
(ANOVA) with the type of stimulus (PInt or CInt) as the
within-participant factors and group (PD or HC) as the
between-participants factors. We compared the RME
scores of the PD-MCI and HC groups using a one-way
ANOVA.
Subsequently, PD-MCI AI task performance (accuracy
and RT) was analysed using repeated-measures ANOVA,
with the type of stimulation (active or sham) and the
type of stimulus (PInt or CInt) as within-participant fac-
tors, and sex as the between-participants factor. Sensa-
tion scores were compared between active tDCS and
sham tDCS using a Wilcoxon matched-pair test. Statis-
tical significance was set at p < 0.05.
Finally, a regression analysis was performed for corre-
lations between ToM performance (AI task mean per-
formance in the sham tDCS condition and the RME
score) and neuropsychological assessment measures in
order to investigate the relationship between ToM and
cognitive abilities. We also performed regression analysis
between active tDCS-induced changes in the AI task
(RTs in the sham tDCS condition subtracted by those in
the active tDCS condition) and neuropsychological assess-
ment measures to determine whether greater difficulties
in some cognitive abilities influenced the effects of tDCS
on ToM. Statistical significance for regression analysis
was set at p < 0.01 (Bonferroni corrected for the num-
ber of comparisons, p = 0.05/5 = 0.01) for clinical
scales, at p < 0.013 (Bonferroni corrected for the num-
ber of comparisons, p = 0.05/4 = 0.013) for assess-
ments of memory and language and at p < 0.005
(Bonferroni corrected for the number of comparisons,
p = 0.05/11 = 0.005) for attentional and executive func-
tions evaluations.
Statistical power and effect size (Cohen’s d) analyses
were performed using GPower 3.1 [99]. The datasets used
and/or analysed during the current study are available
from the corresponding author on reasonable request.
Results
Behavioural performance on ToM tasks in patients with
PD-MCI and HC
RME task
Analysis of the RME scores revealed a significant effect
of group (F(1,38) = 8.03, p = 0.007, η
2 = 0.17, 1-β = 0.99).
This result indicates that the PD-MCI group performed
Table 2 Demographic and clinical characteristics of patients
with Parkinson’s Disease-mild cognitive impairment (n = 20)
Mean (SD)
Age (years) 65.6 (8.4)
Education (years) 10.3 (4.6)
Sex (male/female) 10/10
Age of onset (years) 58.9 (7.5)
Levodopa-equivalent daily dose (mg) 555.7 (323.1)
Cumulative Illness Rating Scale – severity 1.6 (0.3)
Cumulative Illness Rating Scale – comorbidity 2.9 (1.8)
Unified Parkinson’s Disease Rating Scale III 24.1 (9.5)
Hoehn & Yahr 1.8 (0.7)
Toronto Alexithymia Scale-20 50.7 (14.8)
Interpersonal Reactivity Index 84.4 (13.0)
REM Sleep Behavior Disorder Screening Questionnaire 3.6 (2.4)
Parkinson’s Disease Quality of Life Questionnaire 23.2 (13.0)
Beck Depression Inventory II 11.7 (6.0)
Apathy Evaluation Scale 12.1 (10.2)
Barratt Impulsivity Scale-11 60.5 (8.1)
Standard deviation (SD) is presented in parentheses
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worse than the HC group in this task (HC: 22.9 ± 3;
PD-MCI: 19.7 ± 4). See Fig. 2 for details.
AI task
Accuracy analysis indicated significant effects of group
(F(1,38) = 8.53, p = 0.006, η
2 = 0.18, 1-β = 0.99) and the
type of stimulus (F(1,38) = 4.84, p = 0.033, η
2 = 0.11, 1-β =
0.99). These results indicate that accuracy in the CInt
condition was significantly worse than that in the PInt
condition in both groups, and that the PD-MCI group
had less accuracy in this task than the HC group did
(HC, CInt: 87.1% ± 12, PInt: 94.4% ± 6; PD-MCI, CInt:
79.1% ± 16%, PInt: 80.3% ± 16%).
RT analysis revealed a significant effect of group
(F(1,38) = 6.31, p = 0.016, η
2 = 0.14, 1-β = 0.99). This result
indicates that the PD-MCI group was slower than the
HC group in both CInt and PInt conditions (HC, CInt:
1757.0 ± 387 ms, PInt: 1742.2 ± 321 ms; PD-MCI, CInt:
2391.1 ± 1042 ms, PInt: 2370.5 ± 1084ms). No other ef-
fect reached statistical significance. See Fig. 3 for details.
Effects of tDCS on the AI task in patients with PD-MCI
Accuracy analysis revealed no significant effects of the
type of stimulation (F(1,18) = 1.31, p = 0.27, η
2 = 0.06,
1-β = 0.18), the type of stimulus (F(1,18) = 1.37, p = 0.26,
η2 = 0.07, 1-β = 0.65), or sex (F(1,18) = 3.87, p = 0.07, η
2
= 0.17, 1-β = 0.65), or interactions between factors
(CInt condition: 79% ± 16% [sham tDCS], 75% ± 18%
[active tDCS]; PInt condition: 80% ± 15% [sham
tDCS], 78% ± 18% [active tDCS]).
Fig. 1 a Experimental design. Active or sham tDCS was started 2 min before the beginning of the experimental ToM block and continued
throughout the AI task. In the AI task, a short video was played, and the participant was asked to choose the picture representing a logical story
ending by pushing one of the two buttons on the button box. One example for each stimulus condition (CInt and PInt) is displayed. b Current
flow model for tDCS. The anode was placed over the medial frontal cortex and the cathode was placed between Inion and Oz. The device
utilized two 7- × 5-cm sponge pads represented in the transverse view on the Male 1 model in Soterix HD Targets software (Soterix Medical).
Arrows represent the direction of current flow
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Fig. 2 Score obtained in the Reading the Mind in the Eyes task in patients with PD-MCI and HC plotted separately. The patients with PD-MCI had
significantly worse accuracy than the HC did. Asterisks indicate significant effects (p < 0.05)
Fig. 3 Reaction times a and accuracy b in the AI task (CInt and PInt conditions) in patients with PD-MCI and HC plotted separately. The patients with
PD-MCI had significantly worse accuracy and RTs in the CInt and PInt conditions than the HC did. Asterisks indicate significant effects (p < 0.05)
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RT analysis revealed a significant effect of the type of
stimulation (active vs. sham) (F(1,18) = 6.21, p = 0.022,
η2 = 0.26, 1-β = 0.99). No other effect reached statis-
tical significance. These results indicate active tDCS
induced shorter RTs than sham tDCS in both CInt and
PInt conditions (Active tDCS, CInt: 2096.1 ± 727ms, PInt:
2096.0 ± 939ms; Sham tDCS, CInt: 2391.1 ± 1042ms,
PInt: 2370.5 ± 1084ms) (Fig. 4).
Sensations questionnaire
Responses to the sensations questionnaire completed by
patients with PD-MCI at the end of each stimulation
session revealed that all of the patients tolerated the
stimulation well. A Wilcoxon matched pairs test re-
vealed that perceptual sensations reported after the ac-
tive and sham stimulation sessions were not significantly
different (T = 13.5, z = 1.73; p = 0.08). There was thus no
reason to reject the blinded nature of this study.
Correlation analysis between ToM performance and
apathy, alexithymia, and neuropsychological assessment
in patients with PD-MCI
We used ToM performance (AI task in sham tDCS con-
dition and RME score) as the predictor variable and ap-
athy, alexithymia, or neuropsychological assessment as
the criterion variable. No significant correlations were
found with RME score as the predictor variable.
AI task RT predicted performance on the Stroop task
(Time: r = 0.80, p < 0.0001; Errors: r = 0.79, p < 0.0001),
performance on the FAB (r = − 0.67, p = 0.003) and
time score of the Response Flexibility task of TEA bat-
tery (r = 0.70, p = 0.002), with poorer frontal-executive
abilities associated with longer RTs in the AI task (see
Fig. 5). No significant correlations were found between
AI task accuracy and apathy, alexithymia, or other
neuropsychological scores.
Correlation analysis between active tDCS-induced
changes in the AI task and apathy, alexithymia, and
neuropsychological assessment in patients with PD-MCI
Apathy, alexithymia, or neuropsychological assessment
was used as the predictor variable, and active
tDCS-induced changes in the AI task were used as the
criterion variable.
No significant correlations were found.
Discussion
The aims of the present study were threefold. We hy-
pothesized that, in patients with PD-MCI, ToM task per-
formance would i) be worse than that in HC, ii)
correlate with executive functioning, and iii) be en-
hanced by active tDCS over the MFC when compared to
sham. Our results support the above hypotheses, as fol-
lows: i) In the communicative intentions and private
Fig. 4 Effects of tDCS on reaction times in the AI task in patients with PD-MCI under the active tDCS and sham tDCS conditions (CInt and PInt
conditions plotted separately). The reaction times of patients with PD-MCI in the AI task decreased after active tDCS over the MFC (Fpz site, with
the cathode between Oz and Inion) when compared to sham stimulation in both the CInt and Pint conditions. Asterisks indicate significant
effects (p < 0.05)
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intentions ToM tasks, the patients were slower and less
accurate than the HC. ii) We found relationships between
ToM and executive functioning. In particular, ToM abil-
ities were poorer in patients with fronto-executive difficul-
ties as assessed by the FAB and the Stroop task. iii) In
patients with PD-MCI, a single session of active tDCS
over the MFC led to significant shortening of latency in
ToM tasks when compared to sham stimulation. We
found no effects of tDCS on accuracy.
Until now, no study had investigated the effects of tDCS
on ToM abilities in patients with PD-MCI, and only a few
researchers have used tDCS in patients with PD. These
researchers mainly focused on the treatment of motor [54,
57, 100–104] and cognitive symptoms [55, 58, 59, 105].
Our findings corroborate previous studies showing
marked difficulties in the domain of ToM in patients with
PD [24–29]. In particular, while neuropsychological stud-
ies have reported heterogeneous and controversial find-
ings regarding affective ToM ability in patients with PD
[106], there is consistent evidence for significant cognitive
ToM impairments in these patients [26, 27, 107–109]. As
recently shown by Bora, Walterfang, and Velakoulis [110],
this may partially be explained by frontal-executive diffi-
culties, which represent a crucial non-motor symptom of
patients with PD-MCI. There is a significant relationship
between ToM and executive functioning, even though the
exact nature of this relationship between these two
distinct domains remains at least partially unknown [111,
112]. At any rate, evidence from neuropsychological stud-
ies on ToM abilities suggests that executive functioning is
necessary to perform cognitive ToM tasks [113–116].
Again, this observation is in line with our finding showing,
in a sample of patients with PD-MCI, significant correla-
tions between the RT to the AI task and both the FAB
score and the interference effect on time and on error of
the Stroop task.
Several lines of evidence suggest that the MFC might be
critical for social cognition [46, 117, 118] and that increased
MFC activity might result in enhanced social cognition
[46]. The mechanisms underlying the effects of tDCS are
not yet entirely understood, but might involve changes in
the activities of some neurotransmitters [42, 119]. TDCS
modifies the synaptic microenvironment by modifying syn-
aptic strength (i.e., N-methyl-D-aspartate receptor func-
tioning) or altering gamma-aminobutyric acid-mediated
activity. It induces transient changes in the densities of pro-
tein channels localized to the cortical area below the elec-
trodes, which would in turn interfere with brain excitability
through the modulation of intracortical and corticospinal
neuron activity [41, 42, 119]. In particular, the activities
neurotransmitters, especially that of dopamine, seem to in-
fluence the plasticity changes induced by tDCS, as they de-
pend on the relationship between current and the
functioning of neurotransmitter receptors [119–121].
Fig. 5 Significant correlations between reaction time of the Attribution of Intentions task in sham transcranial direct current stimulation condition
and attentional-executive abilities in patients with PD-MCI
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The finding that a single session of active tDCS over
the MFC had a significant effect on ToM performance
in patients with PD-MCI might have important clinical
implications. In fact, evidence for enhancement of ToM
performance by tDCS might lead to a potential interven-
tion approach for this disease. However, we acknowledge
that the present study has some limitations. First, it is
important to underline that the enhancement we found
was limited to RTs and that we observed no effect on ac-
curacy. Another shortcoming is that we classified
PD-MCI through a global scale (PD-CRS; [3]). A limita-
tion in terms of the stimulation protocol is that we ap-
plied a single-session online tDCS design that focuses on
short-term improvements induced by a single session of
stimulation, typically delivered on-line during the task.
The adoption of multiple sessions of tDCS could be used
to investigate the long-term effects of stimulation, which
are particularly interesting in neurodegenerative patients.
Hence, further studies are needed in order to conclu-
sively demonstrate the potential for the induction of
long-term neuromodulatory effects using brain stimula-
tion. In particular, the same protocol might be applied to
PD-MCI patients to elucidate long-term improvements
in ToM performance. Moreover, future studies including
larger cohorts of patients at different stages of disease
should be conducted before firm conclusion can be
drawn. These interesting studies could better investigate
the possibility to induce also effects on accuracy in
addition to reaction times modulation. As known, tDCS
is a non-invasive brain stimulation technique character-
ized by limited focality and several methodological fac-
tors, such as type of protocols design, target area,
polarity and number of sessions, that can potentially in-
fluence the variability of behavioural and physiological
outcomes [42, 122]. Accordingly, a further limit is repre-
sented by the lack of a control active stimulation site
that should be considered in future studies to further
confirm the specificity of the MFC for the present re-
sults on ToM tasks.
Conclusion
Despite the limitations described, our findings show for
the first time that active tDCS applied over the MFC
could be useful for enhancing cognitive ToM ability in
patients with PD-MCI. Our findings suggest that
non-invasive brain stimulation could be used in an at-
tempt to ameliorate the ToM deficits observed in these
patients. Of course, further studies are needed to deter-
mine whether the effects found here are clinically mean-
ingful. Nevertheless, the present study significantly
contributes to the emergent evidence suggesting that
tDCS may be used to treat PD [44, 123] and to improve
social cognition [51, 124].
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